• This patent protects the use of glenzocimab in thrombotic diseases until 2036
• This patent has already been granted in the United States and Singapore and is in the process of being granted in other countries such as Japan
To receive all of Acticor Biotech’s financial information in real time, send a request by email to [email protected]
Paris, France, June 29, 2022 – 6:00 p.m. CEST – ACTICOR BIOTECH (ISIN: FR0014005OJ5 – ALACT), a clinical-stage biotechnology company specializing in the development of innovative drugs for the treatment of cardiovascular emergencies, in particular stroke cerebral, announces that the European Patent Office (EPO) has issued a new patent that strengthens Actior Biotech’s patent portfolio. It ensures the protection of glenzocimab in thrombotic diseases in Europe until 2036.
This grant in Europe completes those already obtained in November 2020 in the United States and in November 2021 in Singapore, also protecting glenzocimab until 2036. The patent is also being examined in other countries such as Japan.
To date, three patent families, comprising 4 issued patents and 33 pending patent applications, protect glenzocimab and its use.